Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study

The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-tumor activity of metronomic oral paclitaxel solution in patients with advanced HER2-negative breast cancer who have previously received systemic anti-cancer treatments. The main questions this study aims to answer are: What doses of metronomic oral paclitaxel solution can be safely administered to patients with advanced HER2-negative breast cancer? How well does metronomic oral paclitaxel solution control tumor growth? What side effects and treatment-related medical problems occur during treatment?

Trial Details

NCT ID
NCT07602907
Phase
PHASE2
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Paclitaxel Oral Solution (50mg/qd)
  • Paclitaxel Oral Solution (100mg/TIW)
  • Paclitaxel Oral Solution (OTD)
  • Paclitaxel Oral Solution (150mg/TIW)
  • Paclitaxel Oral Solution (200mg/TIW)
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age ≥ 18 years, male or female. 2.Histologically confirmed unresectable locally advanced, recurrent, or metastatic HER2-negative breast cancer, reg…
  • Patients have received 1-4 prior lines of systemic anti-tumor therapy for recurrent or metastatic disease.
  • Line of therapy is defined as a systemic treatment regimen for recurrent or metastatic disease. First-line therapy is the first regimen used in the…
  • Neoadjuvant or adjuvant therapy is not counted as a treatment line.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →